Why test the cancer?
Every cancer has its own instruction book , written in its genes and proteins. Tests on the biopsy read parts of this book, to find targets for specific medicines and to predict which treatments will work. Two people with the same cancer, in the same organ and at the same stage, may need very different treatment because of these results.
The main tests
Tap a test to see what it is and what it shows.
IHC (stains on the biopsy) MMR / MSI NGS (tissue) Liquid biopsy FISH and PCR Inherited (germline) test
IHC (stains on the biopsy) Special stains on the biopsy tissue, done in the pathology lab.
ER, PR and HER2 in breast cancer; HER2 in stomach cancer.PD-L1 : helps predict benefit from immunotherapy.MMR proteins : see MSI.Results in a few days.
MMR / MSI Checks whether the cancer's DNA repair system (mismatch repair) is working.
dMMR or MSI-high cancers respond very well to immunotherapy.Done for every bowel and womb cancer, and many others. Can be a clue to Lynch syndrome , an inherited condition. Lynch syndrome NGS (tissue) Next-generation sequencing reads many genes in the cancer at once, on the biopsy tissue.
Finds mutations such as EGFR, ALK, ROS1, KRAS, BRAF, RET, NTRK, HER2, BRCA and others, each with its own medicine. Mainly for advanced cancer, or when the result changes the treatment. Results in about 2 to 3 weeks. Liquid biopsy NGS on a blood sample , picking up small pieces of cancer DNA in the blood.
Useful when a new biopsy is difficult, or when tissue is not enough. Also used to find new mutations when a treatment stops working. A negative result does not always rule out a mutation; sometimes tissue testing is still needed. FISH and PCR Focused tests for one change, such as HER2 amplification (FISH) or EGFR mutation (PCR).
Faster and cheaper, but look at only one or a few genes. Inherited (germline) test A blood or saliva test for mutations you were born with, such as BRCA1, BRCA2 or Lynch syndrome genes.
Matters for your treatment, your future risk and your family. Genetic testing
From biopsy to treatment plan
This is why we sometimes ask you to wait for all reports before starting treatment.
Biopsy A small piece of the cancer is taken. Pathology Confirms the cancer and its type (3 to 5 days). IHC and other stains ER, PR, HER2, PD-L1, MMR (a few days more). NGS, if needed For advanced cancer (2 to 3 weeks). Tumour board All results discussed together. Your plan Explained to you and your family.
What a result can mean
Result What it can mean A target is found A targeted tablet or drip that works better, or has fewer side effects, than standard chemotherapy. MSI-high, or high PD-L1 or TMB Immunotherapy is more likely to work. An inherited mutation is suspected A blood test for you, and testing for your family. Nothing treatable is found Still useful: it avoids medicines that would not work, and standard treatment is chosen. It may make you eligible for a clinical trial.
Practical points
These tests are expensive, so we advise the tests that can change your treatment . Please ask us before getting tests done elsewhere. Ask the lab to keep your biopsy blocks and slides ; they can be used for more tests later or for a second opinion. Some tests are repeated later, when the cancer changes.
Already on treatment?
Choose your regimen to see the side effects of your own medicines, when to expect them, and what helps.
My treatment
How your treatment is decided
Every new patient's case is discussed at our multidisciplinary tumour board . This is a meeting where the medical oncologist, surgical oncologist, radiation oncologist, radiologist and pathologist, and when needed the nuclear medicine and palliative care teams, review your scans, biopsy and reports together.
Cancer treatment often combines surgery, radiotherapy and medicines. The board agrees on the right treatments and the right order .
You get one agreed plan, based on the latest evidence, instead of separate opinions.
Cases are discussed again when the situation changes, for example after surgery or if a scan shows new findings.
Written and medically reviewed by Dr Prathyusha Eaga, MD, DM (Medical Oncology). Last reviewed: 12 October 2026. Based on NCCN and ESMO guidelines.
Have questions?
Book a hospital visit, a video consultation or a second opinion.